Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 196.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,383 shares of the life sciences company’s stock after purchasing an additional 30,080 shares during the period. International Assets Investment Management LLC’s holdings in Illumina were worth $59,180,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Primecap Management Co. CA grew its position in shares of Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after buying an additional 1,997,010 shares in the last quarter. Millennium Management LLC boosted its stake in Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after acquiring an additional 1,118,747 shares during the last quarter. Capital World Investors grew its holdings in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after acquiring an additional 801,814 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Illumina in the 2nd quarter valued at about $77,628,000. Finally, Findlay Park Partners LLP bought a new position in shares of Illumina during the first quarter worth about $100,120,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $141.95 on Monday. The stock has a market cap of $22.61 billion, a price-to-earnings ratio of -7.41 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $151.40. The stock’s 50 day moving average price is $134.53 and its 200 day moving average price is $121.57.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the business earned $0.32 EPS. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 3.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several research reports. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Wednesday, August 28th. Barclays lifted their price objective on shares of Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 15th. Piper Sandler dropped their target price on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Finally, Robert W. Baird lifted their price target on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $154.33.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.